Janus Henderson Group PLC Sells 257,759 Shares of Globus Medical, Inc. $GMED

Janus Henderson Group PLC lessened its stake in shares of Globus Medical, Inc. (NYSE:GMED) by 3.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 7,294,878 shares of the medical device company’s stock after selling 257,759 shares during the period. Janus Henderson Group PLC owned 0.05% of Globus Medical worth $636,916,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Bank of Montreal Can raised its stake in shares of Globus Medical by 15,317.1% during the fourth quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock valued at $294,519,000 after acquiring an additional 3,351,380 shares in the last quarter. William Blair Investment Management LLC raised its stake in shares of Globus Medical by 17.2% during the third quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock valued at $161,454,000 after acquiring an additional 414,134 shares in the last quarter. Sculptor Capital LP raised its stake in shares of Globus Medical by 31.9% during the second quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock valued at $162,936,000 after acquiring an additional 667,850 shares in the last quarter. Alliancebernstein L.P. raised its stake in shares of Globus Medical by 1,303.9% during the third quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock valued at $117,700,000 after acquiring an additional 1,908,795 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Globus Medical by 72.1% during the third quarter. Dimensional Fund Advisors LP now owns 2,011,104 shares of the medical device company’s stock valued at $115,166,000 after acquiring an additional 842,547 shares in the last quarter. Institutional investors own 95.16% of the company’s stock.

Globus Medical Stock Down 2.9%

Shares of GMED stock opened at $75.29 on Thursday. The firm has a market cap of $10.22 billion, a price-to-earnings ratio of 17.51, a PEG ratio of 1.60 and a beta of 0.95. The company’s 50 day moving average is $85.09 and its 200 day moving average is $87.80. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $101.40.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.20. The company had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. Globus Medical’s revenue was up 27.0% compared to the same quarter last year. During the same period last year, the company posted $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Analysts anticipate that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

Insider Transactions at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director directly owned 510,175 shares of the company’s stock, valued at $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 18.38% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

GMED has been the subject of several research analyst reports. Piper Sandler decreased their price target on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research note on Monday. Barclays lifted their price target on shares of Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Truist Financial set a $115.00 price target on shares of Globus Medical in a research note on Wednesday, February 25th. Zacks Research raised shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Finally, Wells Fargo & Company cut their price objective on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $105.00.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.